Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed

Published:2015-12 Issue: Volume:769 Page:127-133
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Liu Rui,Xu Kang-Ping,Tan Gui-Shan

Funder

National Natural Science Foundation of China

The Science and Technology Planning Project of Hunan Province, China

Social Development of Science and Technology of Hainan Province, China

Key Project of Science and Technology of Hunan Province, China

Publisher

Elsevier BV

Subject

Pharmacology

Reference77 articles.

1. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer;Altorki;J. Clin. Oncol.,2003

2. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association;Antman;Circulation,2007

3. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer;Argiris;Invest. New Drug.,2006

4. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line;Arico;J. Biol. Chem.,2002

5. Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer;Arúajo;Cancer Invest.,2009

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological and pharmacological functions of the metabolites of polyunsaturated fatty acids mediated by cyclooxygenases, lipoxygenases, and cytochrome P450s in cancers;Pharmacology & Therapeutics;2024-04

2. COX‐2 in lung cancer: Mechanisms, development, and targeted therapies;Chronic Diseases and Translational Medicine;2024-03-12

3. Deciphering the potential therapeutic targets and mechanisms of jaranol for the treatment of COVID-19 and lung adenocarcinoma;Arabian Journal of Chemistry;2024-03

4. Microwave-assisted synthesis of celecoxib nanocomposites for enhancement of solubility and colon cancer targeting;Nano-Structures & Nano-Objects;2024-02

5. The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive;International Journal of Molecular Sciences;2023-10-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3